Hims & Hers Lands Eli Lilly's Weight-Loss Drugs on Its Platform — But Can Revenue Growth Outrun Shrinking Margins?

Shares surged as much as +6.4% to $25.60 after Hims & Hers and Eli Lilly formalized a deal to sell Lilly's blockbuster obesity drugs directly through the telehealth platform. The agreement plugs the company's last major product gap — but it also doubles down on a branded-drug strategy that has been crushing profitability for the past year.

• Lilly's Drugs No Longer Require Patients to Leave the Site — Previously, patients who wanted Lilly's drugs on the Hims & Hers platform had to leave the site and go to Lilly's own cash-pay platform, LillyDirect. Now, eligible patients who receive prescriptions from licensed providers on the platform will access Lilly's medications at self-pay prices of $149/month for Foundayo (a daily pill) and $299/month for Zepbound (a weekly injection). Removing that friction should boost conversion rates and keep patients inside the Hims ecosystem.

• Both Major GLP-1 Makers Are Now on Board — The platform already sells Wegovy from Novo Nordisk, so Leerink Partners analyst Michael Cherny called the deal "a clear positive" — it completes Hims & Hers' push for access to both leading GLP-1 makers. That breadth matters: Lilly says 40% to 45% of Zepbound sales go through self-pay channels , a large and growing pool of potential customers. U.S. Zepbound revenue alone rose 48% to $5.3 billion in Q3 2026.

• The Margin Problem Isn't Going Away — This is the tension investors should watch. Gross margin fell to 64% from 76% a year ago, flipping a $42.5 million profit into an $86.3 million net loss in a single year. Selling branded drugs at Lilly's fixed prices gives Hims far less profit per sale than its old compounded alternatives. Neither company disclosed how the economics of each sale are split.

In return, Hims & Hers committed not to offer compounded copies of Lilly's GLP-1 drugs in the future — permanently closing the door on higher-margin knockoffs.

• Earnings in Three Days Will Be the Real Test — Q3 results arrive November 9; investors should watch gross margin against the 63.8% Q2 floor, adjusted EBITDA against the $75–$95 million guide, and what management says about the Lilly deal's economics.

Full-year 2026 revenue guidance stands at $3.1–$3.3 billion , an impressive top line — but one that means little if margins keep sliding. The Lilly partnership validates Hims as a distribution channel; whether it validates the stock depends entirely on the spread between what it sells drugs for and what it keeps.